Nolato AB (publ) (LON:0OA9)

London flag London · Delayed Price · Currency is GBP · Price in SEK
50.10
+1.35 (2.77%)
At close: May 13, 2026
Market Cap1.08B -0.8%
Revenue (ttm)745.31M -3.2%
Net Income60.40M +9.2%
EPS0.22 +8.9%
Shares Outn/a
PE Ratio17.81
Forward PE16.05
Dividend0.14 (0.28%)
Ex-Dividend DateMay 7, 2026
Volume4,641
Average Volume52,956
Open48.43
Previous Close48.75
Day's Range48.43 - 50.35
52-Week Range45.82 - 64.65
Beta0.74
RSI40.89
Earnings DateMay 6, 2026

About Nolato AB

Nolato AB (publ) develops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products in Europe, Asia, North America, and internationally. It operates through the Medical Solutions and Engineered Solutions segments. The company offers catheter balloons; breathing bags; non-conductive sealing and damping silicone products; primary plastic packaging for medicines; and crimp and dropper bottles. It also provides thermal heating pads, gap fillers, and paste under the Compatherm brand; Autolys M products, deep well plates, micro... [Read more]

Industry Miscellaneous Plastics Products
Founded 1938
Employees 5,343
Stock Exchange London Stock Exchange
Ticker Symbol 0OA9

Financial Performance

In 2025, Nolato AB's revenue was 9.46 billion, a decrease of -2.09% compared to the previous year's 9.66 billion. Earnings were 777.00 million, an increase of 18.09%.

Financial numbers in SEK Financial Statements

News

Nolato AB Earnings Call Transcript: Q1 2026

Q1 2026 saw 3% organic growth and stable margins despite currency headwinds and rising input costs. Medical Solutions led with 5% growth, while Engineered Solutions and materials segments also performed well. Margin normalization is expected by Q3 as cost increases are passed on.

7 days ago - Transcripts

Nolato AB Earnings Call Transcript: Q4 2025

Q4 2025 saw 2% sales growth adjusted for currency, with Medical Solutions up 5% and Engineered Solutions down 1%. Margins improved year-over-year, but were impacted by currency headwinds and higher material costs. CapEx and M&A activity remain elevated.

3 months ago - Transcripts

Nolato AB Earnings Call Transcript: Q3 2025

Organic growth and margin improvements drove a 20% EBITDA increase, with strong performance in both Medical and Engineered Solutions. Ongoing expansions and investments support future growth, while the materials business faces continued pressure from the automotive sector.

7 months ago - Transcripts

Nolato AB Earnings Call Transcript: Q2 2025

Sales grew 4% year-over-year to nearly SEK 2.4 billion, with EBITDA margin up to 11.6% and operating profit rising 13%. Medical Solutions led growth, supported by global expansion and margin improvements, while Engineered Solutions saw gains in consumer electronics and hygiene.

10 months ago - Transcripts